EP0587775A4 - Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene. - Google Patents

Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene.

Info

Publication number
EP0587775A4
EP0587775A4 EP9292913615A EP92913615A EP0587775A4 EP 0587775 A4 EP0587775 A4 EP 0587775A4 EP 9292913615 A EP9292913615 A EP 9292913615A EP 92913615 A EP92913615 A EP 92913615A EP 0587775 A4 EP0587775 A4 EP 0587775A4
Authority
EP
European Patent Office
Prior art keywords
mycobacteria
induction
ctl responses
antigens expressed
foreign antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP9292913615A
Other languages
English (en)
French (fr)
Other versions
EP0587775A1 (de
Inventor
Charles K Stover
Cruz Vidal Dela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP0587775A1 publication Critical patent/EP0587775A1/de
Publication of EP0587775A4 publication Critical patent/EP0587775A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP9292913615A 1991-06-06 1992-06-01 Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene. Withdrawn EP0587775A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71164391A 1991-06-06 1991-06-06
US711643 1996-09-10

Publications (2)

Publication Number Publication Date
EP0587775A1 EP0587775A1 (de) 1994-03-23
EP0587775A4 true EP0587775A4 (de) 1994-11-02

Family

ID=24858927

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9292913615A Withdrawn EP0587775A4 (de) 1991-06-06 1992-06-01 Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene.

Country Status (4)

Country Link
EP (1) EP0587775A4 (de)
AU (1) AU2185592A (de)
CA (1) CA2110682A1 (de)
WO (1) WO1992021376A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678034B1 (de) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Induktion der antworten zytotoxischer t-lymphozyten
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
AU1097795A (en) 1993-11-23 1995-06-13 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
GB9426153D0 (en) * 1994-12-23 1995-02-22 Medical Res Council Improvements in or relating to vaccines
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1105490A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
EP1282702B1 (de) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
ES2284681T3 (es) 2000-08-25 2007-11-16 Aventis Pasteur Limited Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae.
WO2002036777A1 (en) 2000-11-02 2002-05-10 The National University Of Singapore aopB GENE, PROTEIN, HOMOLOGS, FRAGMENTS AND VARIANTS THEREOF, AND THEIR USE FOR CELL SURFACE DISPLAY
AU2002364161A1 (en) 2001-12-12 2003-06-23 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
MX2011006922A (es) 2008-12-24 2012-06-12 Netherlands Vaccine Inst Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia.
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
CN104144940B (zh) * 2011-04-18 2018-06-26 明知大学工业和学术合作基金会 来自野野村菌的环肽、其制备方法以及含有该环肽的用于预防或治疗分支杆菌相关疾病的药物组合物
US9717781B2 (en) 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
EP2895501B1 (de) 2012-09-17 2017-01-18 Novartis Tiergesundheit AG Salmonid alphavirus und verwendungen davon
US9809863B2 (en) 2012-11-02 2017-11-07 Elanco Tiergesundheit Ag Flavivirus associated with Theiler's disease
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
JP6498210B2 (ja) 2013-12-29 2019-04-10 チュアラボ オンコロジー, インコーポレーテッドCurelab Oncology, Inc. 炎症関連疾患の治療と予防のためのｐ６２／ｓｑｓｔｍ１に関する方法と組成物
ES2847311T3 (es) 2014-08-05 2021-08-02 MabQuest SA Reactivos inmunológicos que se unen a PD-1
CA3045756A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
EP3964529A1 (de) 2016-01-22 2022-03-09 Mabquest SA Nicht-blockierende pd1 spezifische antikörper
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
EP3996815A2 (de) 2019-07-15 2022-05-18 Lausanne University Hospital Hiv-bindemittel
TW202206098A (zh) 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
WO2023034804A1 (en) 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANNA ALDOVINI ET AL.: "Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines", NATURE, vol. 351, no. 6326, 6 June 1991 (1991-06-06), LONDON GB, pages 479 - 482 *
Annual meeting on modern approaches to new vaccines, 8th, Cold Spring Harbor, N. Y., September, 1990 *
C.K. STOVER ET AL.: "New use of BCG for recombinant vaccines", NATURE, vol. 351, no. 6326, 6 June 1991 (1991-06-06), LONDON GB, pages 456 - 460 *
See also references of WO9221376A1 *
VIDAL F. DE LA CRUZ ET AL.: "Humoral and cellular immune responses to recombinant Mycobacteria (BCG)", VACCINES 91: MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, 1991, pages 399 - 402 *

Also Published As

Publication number Publication date
CA2110682A1 (en) 1992-12-10
AU2185592A (en) 1993-01-08
EP0587775A1 (de) 1994-03-23
WO1992021376A1 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
EP0587775A4 (de) Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene.
DE3467093D1 (en) Marine organism extracts and their preparation
GR3022065T3 (en) Novel antibodies and methods for their use
EP0746621A4 (de) Expression von proteinen auf der oberfläche von bakterien
DK99288D0 (da) Slibeemne
OA09809A (en) Mococlonal antibodies to ELAM-1 and their uses.
EP0599479A3 (de) Lactobacillus zur Verbesserung der Immunfunktionen.
GB9109435D0 (en) Improvements in and relating to cookers
AU7575781A (en) Cyclopropane carboxylates and their use as insectides
AU652970B2 (en) Squamous cell carcinoma-like immunoreactive antigen from human female urine
AU8079187A (en) Arrangement in connection with induction heating
EP0582672A4 (en) Methods to detect and treat diseases caused by bacterial allergens
AU6813190A (en) Reversal of female sexual phenotype in poultry
AU1308288A (en) Method to stimulate the immune response to specific antigens
GB9126932D0 (en) Improvements in and relating to cookers
AU1481088A (en) Hot runner device
AU2151092A (en) Vaccines with erythrocytes as antigen carriers
GB2214509B (en) Human monoclonal antibody to p.aeruginosa and gram negative bacteria: its production and use
ZA926340B (en) Induction of CTL responses
ZA887732B (en) Bacterial strain
JPS55125712A (en) Suerlow electric delay line utilizing thin film inductor array by magnetic lift and coupling
EP0587765A4 (de) Induktion der immunantwort gegen das tetanustoxin durch verarbeitung von mycobakterien, die das tetanustoxin oder fragmente davon exprimieren.
AU1421492A (en) Ovine adipocyte antigens and their use in the immunological control of fat
Marshall Responses to lactation
AU2912192A (en) Waterproof sheet to draw infant developing curve

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 19940916

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

18W Application withdrawn

Withdrawal date: 19941021